M-3814 (Nedisertib) is an orally available, highly potent and selective inhibitor of DNA-dependent protein kinase (DNA-PK). It targets tumor cell growth and survival by inhibiting a critical Double-Strand Breaks (DSB) DNA damage repair mechanism. M3814 sensitizes multiple tumor cell lines to radiation therapy in vitro, and strongly potentiates the antitumor activity of ionizing radiation (IR) in vivo (Xenotransplanted Tumors in Nude Mice) with complete tumor regression applying a clinically relevant fractionated radiation regimen. It is currently in clinical evaluation.

Note: This item is currently suspended at the request of the developer. You might request a quotation for contract research synthesis. Please contact us for conditions and more detailed information.

KEYWORDS: M-3814 | Supplier | DNA-PK inhibitor | Nedisertib | MSC2490484A | M 3814 | M3814 | CAS [1637542-33-6] | DNA-RNA | DNA-PK | Inhibitor | Enzymes